Since our data focused only on colon cancer therapy, further studies are required to explore the use of these vectors to gene therapy for other types of cancer that are loss of IGF2 imprinting, such as hepatoma, lung cancer, breast cancer, leiomyosarcoma, osteosarcoma, leukemia and Wilms’ tumor. This evidence concerns the gene IGF2 and lung carcinoma.